Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Xtent, Inc.
Shanghai’s biopharma sector has started to regain momentum and is beginning to see its innovation bets paying off, with support from the local government.
Private Company Edition: Acelyrin will use its latest funding for Phase III development of izokibep in inflammatory diseases. Also, ArsenalBio raised $220m to take its programmable cell therapies into the clinic and RayzeBio’s $160m series D round will fund clinical trials for its radiopharmaceuticals.
Plagued by a scandal which gained global attention a few years go, the gene therapy sector has recovered and is now thriving in China. But a drive for innovation, combined with ready cash for aspiring start-ups, may not translate into leaps and bounds in the field due to challenges unique to these latest treatments, including manufacturing, durability and coverage.
Nanjing-based Chinese biotech says it has had a US clinical hold put in place for it CAR-T, amid broader challenges for China's cell therapy sector and more measured reaction to the setback than the recent immuno-oncology decision in the US.
- Implantable Devices